Ocular Pharmacotherapy in the Elderly

farmakoloji-11-2-2023-wos

Mehmet Orkun SEVİKa , Berna TERZİOĞLU BEBİTOĞLUb

aMarmara University Faculty of Medicine, Department of Ophthalmology, İstanbul, Türkiye
aMarmara University Faculty of Medicine, Department of Medical Pharmacology, İstanbul, Türkiye

ABSTRACT
The World Health Organization states that everyone who lives long enough will experience an eye condition requiring care at least once in their lifetime. The population’s mean age is rising daily with the improving health conditions and increasing life expectancy. Therefore, the prevalence of ophthalmic diseases leading to visual impairment and reduced quality of life is also growing. Ocular pharmacotherapies are considered safe because of their minimal adverse-effect profile. However, there may be severe adverse effects that should be known, especially in patients prone to co-morbidities and polypharmacy, such as geriatric patients. In this review, systemic and local adverse effects of ocular pharmacotherapies in glaucoma, age-related macular degeneration, and diabetic retinopathy, the most common causes of moderate and severe vision loss and blindness in the geriatric population, as well as dry eye disease, which is also frequently seen in the elderly and reduces the quality of life, will be discussed.
Keywords: Diabetic retinopathy; eye diseases; geriatrics; glaucoma; macular degeneration age-related

Referanslar

  1. World report on vision. Geneva: World health organization; 2019. Licence: Cc by-nc-sa 3.0 igo.
  2. Fricke TR, Tahhan N, Resnikoff S, Papas E, Burnett A, Ho SM, et al. Global prevalence of presbyopia and vision impairment from uncorrected presbyopia: Systematic review, meta-analysis, and modelling. Ophthalmology. 2018;125(10):1492-9. [Crossref]  [PubMed]
  3. Trends in prevalence of blindness and distance and near vision impairment over 30 years: An analysis for the global burden of disease study. Lancet Glob Health. 2021;9(2):e130-43.
  4. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to vision 2020: The right to sight: An analysis for the global burden of disease study. Lancet Glob Health. 2021;9(2):e144-60.
  5. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990-2020: A systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221-34.
  6. The international agency for the prevention of blindness (iapb) vision atlas. Country map & estimates of vision loss. [cited 2023 August 20]; Available from: [Link]
  7. Mirza E, Mirza GD, Oltulu R, Okka M, Ozkagnici A. The Frequency and Causes of Blindness in a Rural Region of Central Anatolia of Turkey. Eurasian J Med. 2019;51(3):242-6. [Crossref]  [PubMed]  [PMC]
  8. Küçük E, Yilmaz U, Zor KR. Causes of blindness and moderate to severe visual impairment in niğde, central anatolia, turkey. Erciyes Medical Journal. 2019;41(4):420-4. [Crossref]
  9. Karahan M, Demirtaş AA. Causes of blindness in adults in southern turkey according to health committee reports. Turk J Ophthalmol. 2021;51(3):146-50. [Crossref]  [PubMed]  [PMC]
  10. Mirza GD, Okka M, Mirza E, Belviranlı S. The causes and frequency of monocular and binocular blindness in adults applying to the health committee of a university hospital in central anatolia. Turk J Ophthalmol. 2021;51(5):282-7. [Crossref]  [PubMed]  [PMC]
  11. Umfress AC, Brantley MA, Jr. Eye care disparities and health-related consequences in elderly patients with age-related eye disease. Semin Ophthalmol. 2016;31(4):432-8. [Crossref]  [PubMed]  [PMC]
  12. World health organization. Universal eye health: A global action plan 2014-2019. Geneva: World health organization, 2013. [cited 2023 August 20]; Available from: [Link]
  13. Kitazawa K, Inomata T, Shih K, Hughes JB, Bozza N, Tomioka Y, et al. Impact of aging on the pathophysiology of dry eye disease: A systematic review and meta-analysis. Ocul Surf. 2022;25:108-18. [Crossref]  [PubMed]
  14. Awwad S, Mohamed Ahmed AHA, Sharma G, Heng JS, Khaw PT, Brocchini S, et al. Principles of pharmacology in the eye. Br J Pharmacol. 2017;174(23): 4205-23. [Crossref]  [PubMed]  [PMC]
  15. Adrianto MF, Annuryanti F, Wilson CG, Sheshala R, Thakur RRS. In vitro dissolution testing models of ocular implants for posterior segment drug delivery. Drug Deliv Transl Res. 2022;12(6):1355-75. [Crossref]  [PubMed]  [PMC]
  16. Novack GD, Robin AL. Ocular pharmacology. J Clin Pharmacol. 2016;56(5): 517-27. [Crossref]  [PubMed]
  17. Yellepeddi VK, Palakurthi S. Recent advances in topical ocular drug delivery. J Ocul Pharmacol Ther. 2016;32(2):67-82. [Crossref]  [PubMed]
  18. Cunha-Vaz JG. The blood-ocular barriers: Past, present, and future. Doc Ophthalmol. 1997;93(1-2):149-57. [Crossref]  [PubMed]
  19. Mostafa M, Al Fatease A, Alany RG, Abdelkader H. Recent advances of ocular drug delivery systems: Prominence of ocular implants for chronic eye diseases. Pharmaceutics. 2023;15(6). [Crossref]  [PubMed]  [PMC]
  20. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131-5. [Crossref]  [PubMed]
  21. Anatomy of the eye. In: Neuroscience (Purves D, Augustine GJ, Fitzpatrick D, Katz CL, A. L, McNamara JO, et al., editors), 2nd. ed. Sunderland (MA): Sinauer Associates, 2001.
  22. Labetoulle M, Frau E, Le Jeunne C. Systemic adverse effects of topical ocular treatments. Presse Med. 2005;34(8):589-95. [Crossref]
  23. Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: A pharmacokinetic perspective. Clin Ophthalmol. 2016;10:2433-41. [Crossref]  [PubMed]  [PMC]
  24. Urtti A, Rouhiainen H, Kaila T, Saano V. Controlled ocular timolol delivery: Systemic absorption and intraocular pressure effects in humans. Pharm Res. 1994;11(9):1278-82. [Crossref]  [PubMed]
  25. Broadway DC, Cate H. Pharmacotherapy and adherence issues in treating elderly patients with glaucoma. Drugs Aging. 2015;32(7):569-81. [Crossref]  [PubMed]
  26. Goldberg I, Moloney G, McCluskey P. Topical ophthalmic medications: What potential for systemic side effects and interactions with other medications? Med J Aust. 2008;189(7):356-7. [Crossref]  [PubMed]
  27. Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. Tfos dews ii report executive summary. Ocul Surf. 2017;15(4):802-12. [Crossref]  [PubMed]
  28. Pucker AD, Ng SM, Nichols JJ. Over the counter (otc) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev. 2016;2(2):Cd009729. [Crossref]  [PubMed]  [PMC]
  29. Diamond JP. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging. 1997;11(5):352-60. [Crossref]  [PubMed]
  30. Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. Tfos dews ii management and therapy report. Ocul Surf. 2017;15(3):575-628. [Crossref]  [PubMed]
  31. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in sjögren syndrome. Ophthalmology. 1999;106 (4):811-6. [Crossref]  [PubMed]
  32. Roters S, Aspacher F, Diestelhorst M. The influence of dexamethasone 0.1% eye drops on plasma cortisol and acth concentrations after cataract surgery. Ophthalmologica. 1996;210(4):211-4. [Crossref]  [PubMed]
  33. Bahar I, Rosenblat I, Erenberg M, Eldar I, Gaton D, Avisar R, et al. Effect of dexamethasone eyedrops on blood glucose profile. Curr Eye Res. 2007;32 (9):739-42. [Crossref]  [PubMed]  [PMC]
  34. Bahar I, Vinker S, Kaiserman I. The effect of topical steroids on blood glucose profile in diabetic patients. Journal of Clinical & Experimental Ophthalmology. 2011;02. [Crossref]
  35. de Paiva CS, Pflugfelder SC, Ng SM, Akpek EK. Topical cyclosporine a therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019;9(9): Cd010051. [Crossref]  [PubMed]  [PMC]
  36. European Glaucoma Society. Terminology and guidelines for glaucoma. 5th ed. Italy: PubliComm; 2021.
  37. Syed MF, Rehmani A, Yang M. Ocular side effects of common systemic medications and systemic side effects of ocular medications. Med Clin North Am. 2021;105(3):425-44. [Crossref]  [PubMed]
  38. Chuck RS, Dunn SP, Flaxel CJ, Gedde SJ, Mah FS, Miller KM, et al. Comprehensive adult medical eye evaluation preferred practice pattern®. Ophthalmology. 2021;128(1):P1-p29. [Crossref]  [PubMed]
  39. Contreras-Salinas H, Orozco-Ceja V, Romero-López MS, Barajas-Virgen MY, Baiza-Durán LM, Rodríguez-Herrera LY. Ocular cyclopentolate: A mini review concerning its benefits and risks. Clin Ophthalmol. 2022;16:3753-62. [Crossref]  [PubMed]  [PMC]
  40. Gurunathan U. Caution with ocular phenylephrine. Anaesth Intensive Care. 2006;34(5):686-7.
  41. Coleman HR, Chan CC, Ferris FL, 3rd, Chew EY. Age-related macular degeneration. Lancet. 2008;372(9652):1835-45. [Crossref]  [PubMed]
  42. Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023;6(6): Cd009300. [Crossref]  [PubMed]  [PMC]
  43. Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020;5(5):Cd012208. [Crossref]  [PubMed]  [PMC]
  44. Han X, Chen Y, Gordon I, Safi S, Lingham G, Evans J, et al. A systematic review of clinical practice guidelines for age-related macular degeneration. Ophthalmic Epidemiol. 2023;30(3):213-20. [Crossref]  [PubMed]
  45. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the european society of retina specialists (euretina). Ophthalmologica. 2017;237(4):185-222. [Crossref]  [PubMed]
  46. Wilkinson CP, Ferris FL, 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677-82. [Crossref]  [PubMed]
  47. Romero-Aroca P. Managing diabetic macular edema: The leading cause of diabetes blindness. World J Diabetes. 2011;2(6):98-104. [Crossref]  [PubMed]  [PMC]
  48. Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: New concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27. [Crossref]  [PubMed]  [PMC]
  49. Iovino C, Mastropasqua R, Lupidi M, Bacherini D, Pellegrini M, Bernabei F, et al. Intravitreal dexamethasone implant as a sustained release drug delivery device for the treatment of ocular diseases: A comprehensive review of the literature. Pharmaceutics. 2020;12(8):703. [Crossref]  [PubMed]  [PMC]
  50. Rajesh B, Zarranz-Ventura J, Fung AT, Busch C, Sahoo NK, Rodriguez-Valdes PJ, et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2020;104(1):39-46.. [Crossref]  [PubMed]
  51. Valverde-Megías A, Cifuentes-Canorea P, Ruiz-Medrano J, Peña-García P, Megías-Fresno A, Donate-López J, et al. Systemic effects of repeated intraocular dexamethasone intravitreal implant in diabetic patients: A retrospective study. Diabetes Ther. 2017;8(5):1087-96. [Crossref]  [PubMed]  [PMC]